Integra LifeSciences Holdings (IART)

Return on total capital

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Earnings before interest and tax (EBIT) (ttm) US$ in thousands 32,842 39,824 79,645 98,962 132,446 166,939 206,873 254,396 263,488 250,298 241,673 235,835 265,072 257,427 256,754 216,114 165,101 148,703 72,849 105,283
Long-term debt US$ in thousands 1,087,920 1,132,290 1,723,380 1,742,020 1,395,820 1,419,620 1,333,410 1,337,210 1,300,490 1,381,140 1,385,540 1,389,930 1,388,680 1,387,430 1,386,180 1,484,910 1,408,220 1,414,000 1,472,320 1,478,190
Total stockholders’ equity US$ in thousands 1,545,280 1,521,590 1,534,200 1,597,950 1,587,880 1,579,220 1,683,160 1,674,940 1,804,400 1,724,410 1,660,920 1,615,200 1,684,800 1,631,690 1,574,980 1,529,330 1,514,870 1,397,990 1,349,100 1,341,800
Return on total capital 1.25% 1.50% 2.44% 2.96% 4.44% 5.57% 6.86% 8.45% 8.49% 8.06% 7.93% 7.85% 8.62% 8.53% 8.67% 7.17% 5.65% 5.29% 2.58% 3.73%

December 31, 2024 calculation

Return on total capital = EBIT (ttm) ÷ (Long-term debt + Total stockholders’ equity)
= $32,842K ÷ ($1,087,920K + $1,545,280K)
= 1.25%

The return on total capital for Integra LifeSciences Holdings fluctuated over the quarters analyzed. The trend shows an increase from 3.73% in March 2020 to 8.49% in December 2022. However, there was a decline in the return on total capital in the subsequent quarters, reaching 1.25% by December 2024. This indicates a decrease in the company's ability to generate profits relative to its total capital employed over this period. Monitoring and analyzing the factors driving these fluctuations would be vital for assessing the company's operational efficiency and profitability moving forward.